UK: But Finishing Was Never Part Of The (Paediatric Investigation) Plan...

Last Updated: 12 February 2014
Article by Stephen Duffield and Dr. Hugh Goodfellow

The UK's High Court recently decided upon Dr Reddy's application to revoke the 6 month paediatric extension of Warner-Lambert's SPC for atorvastatin (Lipitor), which is used for lowering blood cholesterol.


SPCs are granted to compensate patent holders for the time taken to obtain marketing authorisation for a medicine covered by a patent. An SPC comes into effect at the end of the patent's term. It extends the protection for the authorised medicine for a period equal to that between the filing date of the patent and the date of the first marketing authorisation, to a maximum of 5 years.

Provision for the extension of SPCs was introduced by Regulation 1901/2006 ("the paediatric regulation") which took effect in January 2007. The regulation's purpose is to encourage research into the use of medicines in children. This research is considered to be important, because, as noted in Recital 3 of the regulation, a lack of information in this area leads to increased risks of adverse reactions, ineffective treatment through under-dosage, and the non-availability to the paediatric population of therapeutic advances, suitable formulations and routes of administration. In this regard, however, there is no requirement that a medicine be authorised for paediatric use for an extension to the SPC to be granted following the research.

The discovery that the medicine is not effective in the paediatric population is also considered valuable information.

Briefly, in order to obtain a paediatric extension, the applicant must complete a number of steps, including the following:

  1. Draw up a draft paediatric investigation plan (PIP) and submit it to the European Medicines Agency (EMA), through the Paediatric Committee (PDCO), for agreement. The PIP should specify the timing and measures proposed to assess the quality, safety and efficacy of the medicine in the paediatric population. In addition, it should describe any measures to adapt the formulation of the medicinal product to make its use more acceptable, easier, safer or more effective. The proposed PIP is assessed by the PDCO, which may request modifications to the plan. The PDCO then adopts an opinion as to whether or not the proposed studies will generate the necessary data, and if they are justified by the envisaged benefits. The EMA issues a decision, annexing the PDCO's opinion.
  2. Apply for a marketing authorisation including the decision agreeing to the PIP, the results of all studies performed and details of all information collected in compliance with the agreed PIP. The competent authority (i.e. the body that grants marketing authorisations) which has received the application verifies that the PIP has been complied with.
  3. Apply to the national patent offices for a paediatric extension to its SPCs, if the applicant has been issued a marketing authorisation indicating compliance with the PIP.

The paediatric extension for atorvastatin

Pfizer had proposed new pharmaceutical forms for oral atorvastatin, which were more appropriate for children aged 6 years and above than the previously authorised film-coated tablet.

The agreed PIP required three clinical studies. The first was a bioequivalence study to check the bioavailability and effectiveness of the new form in comparison to the existing formulation in healthy adult volunteers. The second was a pharmacokinetic study to determine dosing. The third was a 3-year study of safety and efficacy.

The PIP specified that the first study was to be completed by 30th September 2009 and the second study by 30th December 2009. The third study, however, was only required in the PIP to be commenced by 31st March 2009. In due course an extension to the SPC was granted, on the basis of a decision that the studies conducted by Pfizer were in accordance with the PIP, as the first and second studies had been completed and the third study had been started.

The Court's judgment

Three grounds for revocation were advanced by Dr Reddy's, but all were dismissed by the Court.

First, Dr Reddy's argued that the EMA had acted incorrectly by approving a PIP that required Pfizer merely to commence the third study, and as such the PIP was not lawfully approved and Pfizer was not entitled to the extension. However, the Court instead assessed that the relevant question was whether or not the requirements of the PIP had been fulfilled. It judged that Pfizer had indeed complied by completing the first and second studies, and initiating the third study.

Second, Dr Reddy's argued that, pursuant to Article 45(3) of the regulation, a paediatric extension should be granted only when 'significant studies' contained in the PIP have been completed. It alleged that at no stage had any assessment been performed as to whether either of the two completed studies was significant; it further alleged that they were not significant. The Court decided, however, that Article 45(3) was a transitional provision which related to research performed before the regulation came into effect. Accordingly, it did not apply in this case.

Finally, Dr Reddy's argued that even if it was legitimate for the EMA to approve a PIP that required the initiation but not completion of the third study, Pfizer was not entitled to an extension unless it included the results of the completed third study within its marketing authorisation application. Here, the Court considered that this argument also failed once it had been decided that Pfizer had complied with the PIP.

A further issue in this case related to the interpretation of Article 16 of the SPC regulation (Regulation 469/2009), which sets out that the paediatric extension may be revoked if granted contrary to the requirements of Article 36 of the paediatric regulation. Dr Reddy's argued that this would oblige the Court to revoke the extension of the SPC if it had been granted when this article of the paediatric regulation had not been complied with, but Pfizer argued that it merely gave the Court discretion to do so. On this point, the Court also agreed with Pfizer.


This decision is of interest in clarifying the interpretation that the UK courts will take with regard to whether or not a PIP has been completed. As SPCs are dealt with on a national basis, however, there is significant potential for contradictory judgments to be issued in different countries, meaning that it is only when questions of this type have been referred to the Court of Justice for the European Union that the issues raised in this case will be definitively addressed. Indeed, bearing in mind that this legislation is relatively new, it is likely that many further issues of interpretation will be raised in due course. This is even more likely because the paediatric extension extends the SPC and so coverage for the authorised medicine, irrespective of the indication, at the tail-end and hence most valuable part of an SPC's life.

Need advice?

Carpmaels & Ransford LLP is a leading firm of European patent and trade mark attorneys based in London. For more information about our firm and our practice, please visit our website at

This Briefing Note was first published in the IAM IP Newsletter.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions